Vectorite Biomedical

Vectorite Biomedical Current Assets

The Current Assets of Vectorite Biomedical (4170.TWO) as of Nov 5, 2026 is 14.98 M TWD. In the previous year, Current Assets was 208.47 M TWD — a change of -92.81% (lower).

Current Assets

14.98 MTWD

YoY

-92.81%

Last updated:

Current Assets of Vectorite Biomedical is 2025 14.98 M TWD. Current Assets of Vectorite Biomedical was 2024 208.47 M TWD. It decreases by -92.81% lower compared to the previous year.

The Vectorite Biomedical Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
92.17 M TWD
Jan 1, 2019
132.04 M TWD
Jan 1, 2020
99.35 M TWD
Jan 1, 2021
250.32 M TWD
Jan 1, 2022
232.06 M TWD
Jan 1, 2023
223.13 M TWD
Jan 1, 2024
208.47 M TWD
Jan 1, 2025
14.98 M TWD
The Vectorite Biomedical Current Assets history
YEARCurrent AssetsYoY
14.98 MTWD-92.81%
208.47 MTWD-6.57%
223.13 MTWD-3.85%
232.06 MTWD-7.29%
250.32 MTWD+151.96%
99.35 MTWD-24.76%
132.04 MTWD+43.25%
92.17 MTWD-76.18%
387.01 MTWD+86.99%
206.97 MTWD+1.15%
204.62 MTWD-58.66%
494.98 MTWD+24.54%
397.44 MTWD+761.53%
46.13 MTWD+95.68%
23.58 MTWD+283.46%
6.15 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vectorite Biomedical Stock analysis

What does Vectorite Biomedical do? Xinpin Biomedical Co., Ltd. established Xinpin Biomedical Group with the concept of “preventing problems before it happens” and is headquartered in Taipei, New Taipei. The firm offers a range of services including immune cell collection, processing and storage, cell preparation safety testing, anti-cancer immunity testing, original design manufacturer or contract development and manufacturing organization services, related medical consulting, and laboratory quality management. Its product portfolio features dendritic cell vaccines and natural killer cell preparations designed for cancer treatment. Products are mainly sold domestically. Vectorite Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectorite Biomedical stock

Current Assets of Vectorite Biomedical is 14.98 M TWD in 2025.

Current Assets of Vectorite Biomedical changed from 208.47 M TWD to 14.98 M TWD, representing a -92.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Vectorite Biomedical since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Vectorite Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Vectorite Biomedical

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Vectorite Biomedical